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Abstract:  A new concept  for cancer screening has been preliminarily 
investigated. A cancer targeting agent loaded with a near-infrared (NIR) 
dye was topically applied on the tissue to highlight cancer-suspect 
locations and guide optical coherence tomography (OCT) imaging, which 
was used to further investigate tissue morphology at the micron scale. A 
pilot study on ApcMin mice has been performed to preliminarily test this 
new cancer screening approach. As a cancer-targeting agent, poly(epsilon-
caprolactone) microparticles (PCLMPs), labeled with a NIR dye and 
functionalized with an RGD (argenine-glycine-aspartic acid) peptide, were 
used. This agent recognizes the ανβ3 integrin receptor (ABIR), which is 
over-expressed by epithelial cancer cells. The contrast agent was 
administered topically  in vivo  in mouse colon. After incubation, the 
animals were sacrificed and fluorescence-guided high resolution optical 
coherence tomography (OCT) imaging was used to visualize colon 
morphology. The preliminary results show preferential staining of the 
abnormal tissue, as indicated by both microscopy and laser-induced 
fluorescence imaging, and OCT’s capability to differentiate between 
normal mucosal areas, early dysplasia, and adenocarcinoma. Although very 
preliminary, the results of this study suggest that fluorescence-guided OCT 
imaging might be a suitable approach for cancer screening. If successful, 
this approach could be used by clinicians to more reliably diagnose early 
stage cancers in vivo. 
© 2011 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.4580) Optical diagnostics for 
medicine; (170.4500) Optical coherence tomography; (170.6935) Tissue characterization. 
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1. Introduction 
Standard clinical diagnosis of gastrointestinal cancers relies almost  exclusively on 
endoscopic examination followed by pathological evaluation of tissue biopsies collected 
from suspected locations [1,2]. However, endoscopy does not provide the clinician with 
sufficient resolution to detect early-stage, pre-invasive high grade dysplasia or carcinoma in 
situ in small exophytic or flat adenomas. As a result, early stage cancers might be missed in 
high risk patients [3,4]. The sensitivity of traditional white-light endoscopy for cancer 
identification ranges from 47% to 53% [3]. If cancer is detected at later stages when it has 
already spread to regional lymph nodes (stage III), the cure rate degrades significantly [5,6]. 
Therefore, there is a clear need for novel technologies capable of detecting cancers at earlier 
stages, when they are easier to manage. 
Ideally, an improved endoscopic technology that would maintain the existing 
visualization approach, while adding a more sensitive imaging capability and simultaneously 
a quantitative method for non-invasive assessment of tissue morphology in the cancer-
suspect areas could prove to be a more powerful technique for detection of early stage 
cancers. Although such a technology does not exist yet, important steps have been already 
taken by researchers to address this need. For example, to increase imaging sensitivity, new 
strategies based on targeting molecular signatures of cancers were launched in recent years 
[7–11]. Nanoscale or microscale entities are functionalized to recognize molecular signatures 
and provide sensitivity enhancement in either radiological or optical imaging to allow for 
cancer localization [11,12]. With regard to visualization of tissue morphology in cancer 
suspect areas, high-resolution imaging technologies, such as confocal microscopy (CM) and 
optical coherence tomography (OCT) were tested. They both are capable of revealing tissue 
structure alterations at the sub-micron and micron scale, respectively [13,14]. However, OCT 
has the competitive advantage of providing up to 1.5 mm penetration depth, while still 
providing micron scale resolution. This is essential in determining cancer depth spreading. 
Studies in various organs have demonstrated the ability of OCT to differentiate between 
normal and pre-malignant conditions. For example, ovarian cysts, masses, and abnormal 
tissue have been successfully identified with laparoscopic OCT [15] Laryngeal dysplasia and 
malignancy have been successfully imaged with OCT probes during laryngoscopy [16]. 
Intestinal metaplasia and dysplastic Barrett’s esophagus have been evidenced with 
endoscopic OCT [17,18]. Early investigations of OCT in the pancreas have also 
demonstrated the ability of this technology to distinguish the layers of the main duct 
epithelium in inflammatory and malignant diseases and to differentiate between benign and 
malignant cysts [19,20]. Unfortunately, OCT has a relatively small field of view (FOV), on 
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tool is not a practical approach. 
We investigated the potential for  combining molecular markers with fluorescence 
imaging to guide OCT as a means to detect neoplastic changes in colon mucosal layer. Our 
goal was to demonstrate that the combined imaging modalities could improve our ability to 
detect pre-malignant and early malignant lesions that are not identifiable with endoscopy. In 
this paper we demonstrate for the first time that a fluorophore-loaded cancer targeting agent, 
topically applied on colon tissue, is capable of highlighting high grade lesions relative to the 
surrounding non-neoplastic tissue. Thus, fluorescence imaging can be used to guide OCT 
explorations of tissue and detect early cancer markers. The preliminary testing of this 
approach in a mouse model of colon cancer is discussed. 
2. Materials and methods 
2.1. Contrast agent 
A contrast agent comprised of Poly(epsilon caprolactone) (PCL) microspheres, loaded with a 
fluorescent dye and functionalized with an argenine-glycine-aspartic acid (RGD) peptide to 
target cancer receptors, was designed and fabricated by us. The microspheres were designed 
to have a diameter of 1- 2 μm in order to reduce the probability for the contrast agent to be 
taken up by the vascular system and induce systemic toxicity. It has been shown before that 
micron-size particles (MPs) cannot easily penetrate the lympho-endoreticular system [21]. 
The detailed fabrication steps of this contrast agent are presented elsewhere [22]. Briefly, 
the PCLMPs were surface functionalized with RGD with a linear sequence 
ACD/CRG/DCF/CGG/GGG/COOH, which was  synthesized at the research core facility, 
Tufts University, Boston, Massachusetts, USA. This peptide specifically recognizes the 
alpha-V-beta-3 (ανβ3) integrin receptor overexpressed by the pre-cancerous epithelial cells 
[23–26]. Although other sequences  were also tested, this one demonstrated the highest 
affinity to various colon cancer cell lines, e.g., HT-29, SW-480, etc. A key issue we 
addressed was optimization of the RGD peptide concentration on the MP surface in order to 
maximize cell binding. To this end, we used gold nanobeads (10 to 20 nm in size) as a linker 
between RGD and MP surface. The uniform decoration of the MPs with nanometer size gold 
nanobeads turned out to be a very efficient method to achieve high strength binding between 
the peptide and the MP surface. To make these particles “visible” during the endoscopy, we 
encapsulated a near-infrared (NIR) dye (D-12731, Invitrogen USA) in the MP core, which 
becomes fluorescent when illuminated with 785 nm laser radiation. The choice for the NIR 
dye reduces the influence of tissue autofluorescence and improves imaging depth (the 
attenuation coefficient of tissue is significantly lower in the NIR than in the visible 
spectrum). Our approach to perform dye encapsulation and topical administration of the 
contrast, were two important measures to reduce contrast agent toxicity by limiting its spread 
into the body. 
 
Fig. 1. Scanning electron microscope images of the PCLMPs. Gold coverage with 10-20 nm 
nanobeads can be observed in the left side higher resolution image. 
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Multisizer 3, Beckman Coulter (Fullerton CA, USA). The mean size and standard deviation 
were  1.6  μm  and  0.5  μm,  respectively.  A  Scanning  Electron  Microscopy  image  of  the 
PCLMPs is shown in Fig. 1. A Hitachi S-4800 (Hitachi High-Technologies Europe, UK) 
field emission scanning microscope at an acceleration voltage of 20 kV was used. The gold 
coated surface morphology of the freeze-dried PCLMPs was observed in the reflectance 
mode. 
2.2. Instrumentation 
A multimodal imaging instrument was built to test this new approach for cancer screening. It 
is based on a swept-source OCT system, which was modified to add fluorescence and visible 
imaging capabilities. OCT, fluorescence, and visible channels were combined within the 
same optical path to offer perfect co-registration of the images. The schematic and the 
photographs of the instrument are shown in  Fig. 2. The instrument consists of three 
subsystems: OCT system, imaging probe, and system control unit. 
 
Fig. 2. Schematic (A) and photographs (B,C) of the SS OCT system and imaging probe. 
The OCT system uses a sweeping-wavelength light source (Model HS-2000, Santec, 
USA) with a bandwidth of 135 nm, which allows for an axial imaging resolution in tissue of 
about 6 μm. The other elements of this system are the fiber-optic interferometer, the balance 
detection unit, the signal digitizer, and a customized real-time data acquisition and 
processing board, which was specially designed by PSI to allow for fast-rate imaging and 
display of OCT data with a standard PC. Detailed design of this board was presented 
(C) 2011 OSA 1 January 2012 / Vol. 3,  No. 1 / BIOMEDICAL OPTICS EXPRESS  182
#157807 - $15.00 USD Received 7 Nov 2011; revised 7 Dec 2011; accepted 18 Dec 2011; published 19 Dec 2011elsewhere [27]. The OCT imaging frame rate of this instrument is 20 to 50 frames/sec (with 
1024 or 512 A-lines/frame), while the fluorescence imaging frame rate is 5 frames /sec (200 
ms integration time is needed to provide good SNR in the fluorescence mode). Visible 
imaging was performed at video rates. A LabVIEW-based software program was used for 
some image processing, to display the processed OCT images, for configuration and 
communication with the real time board, and other functionality related to user interface. The 
OCT system was integrated into a 19-inch rack for portability at the animal facility. To test 
the fluorescence-guided OCT imaging concept we designed a combined OCT-fluorescence 
imaging probe with a field of view (FOV) of 20 mm x 20 mm in fluorescence mode and 5 
mm x 5 mm in OCT mode. Our approach was to examine samples of admixed tissue (normal 
and tumor) and guide the OCT beam to suspect areas indicated by the combined bright-
field/fluorescence images. A NIR enhanced response camera (Rolera XR, Q-Imaging) was 
used for fluorescence imaging, while a 785 nm laser diode was used for fluorophore 
excitation. A dichroic filter was used to combine the OCT and fluorescence excitation beams 
in the same optical path, while a custom barrier filter with an 800 nm to 850 nm pass-band 
(Chroma Technology Corp.) was placed in front of the camera lens to block the 785 nm 
excitation light. A visible camera was used to ensure proper placement of the sample under 
the imaging objective. The multimodal imaging probe has been designed to provide the same 
working distance (7.5 mm) for all three imaging modalities. 
A side-looking catheter-type probe was designed and built to test feasibility of in vivo 
imaging of colon wall morphology. This was an important step taken by us towards in vivo 
testing of this technology. The outer diameter of this probe is ~640 μm. Probe scanning was 
performed with a custom-designed scanning engine, which provides a high-speed (50 Hz) 
axial scan and a low-speed angular scan. This scanning engine allows for an imaging 
linearity of 98%. The combination of the axial and rotary scan offers high-resolution 3D 
imaging capabilities. A lateral resolution of 15 μm and a maximum axial imaging range of 
1.5 mm were possible with this probe. 
2.3. Imaging protocols 
Fluorescence microscopy was first performed on two cancer cell lines (HT-29 and SW-480) 
to test and optimize the contrast agent. Combined fluorescence-OCT imaging was then 
performed on an animal model of colon cancer (C57BL/6J-ApcMin mice) to preliminarily 
test the proposed fluorescence-guided OCT approach for cancer screening. BALB/c wild-type 
mice were used as controls in this study. 
The cells lines were cultured and planted in chamber slides (Lab-Tek
TM, Thermo Fisher 
Scientific, USA), which have the bottom side made of a microscope cover glass No #1.5. A 
200 μm coverslip was placed on the top of the chamber. The MPs (Au PCL-DiR-RGD) in 
PBS solution (~10 μM concentration) were added and the cells were placed back in the 
incubator for 1 to 2 hours. After incubation the cells were vigorously washed with PBS (3 to 
5 times), while Dulbecco's Modified Eagle Medium (DMEM) was added before being 
transferred to the microscope for imaging. A fully motorized Olympus IX81 microscope was 
used to study cell binding efficacy. Bright field (visible) and fluorescence images were 
collected from the same field of view and correlated. 
The animal study was performed on 15 ApcMin mice and 6 wild-type mice. Four week 
old ApcMin mice were purchased from Jackson Laboratories (Bar Harbor, ME) and aged for 
up to 16 weeks in the animal facility at Northeastern University NEU). Aging was necessary 
because colorectal lesions in these animals start to develop after 8 weeks of age. Wild mice, 
existent in the NEU animal facility, were used as controls. The mice were divided in 3 
groups, each group containing 5 APC mice and 2 wild mice. Group 1 was investigated at the 
age of 8 weeks, group 2 at the age of 12 weeks, and group 3 at the age of 16 weeks. Since a 
microcatheter containing fibers for both OCT and fluorescence imaging was not available for 
the study, 3 APC mice from each group were used for ex vivo fluorescence-guide OCT 
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was performed to determine the feasibility of OCT use for differentiating between various 
pathologies of the colon in live animals. 
Before imaging, the contrast agent was administered in vivo in the animals selected for 
the ex vivo study using a Teflon® tube-based microcatheter with a 1.5 mm outer diameter. 
Mice were anesthetized a few minutes in advance with 2.0% Avertin, administered 
intraperitoneally. The Teflon® tube was lubricated with a water-based lubricant and inserted 
into the anus with the mouse in the dorsal supine position. Then 2 mg PCLMPs mixed up 
with 50 ml of PBS were topically applied (sprayed in the colon). After 2 hrs of incubation, 
the colon was washed three times with PBS to remove non-binding MPs. Subsequently, all 
the mice planned for the ex vivo study were sacrificed by CO2 inhalation and the colon of 
each mouse was dissected longitudinally. Fluorescence imaging was first performed and then 
the tissue was fixed in 10% formalin for histological examination. 
For the in vivo OCT study, images were collected at eight rotation angles separated by 45 
deg. and 4 depths (25, 20, 15, and 10 mm) with respect to the tissue boundary. After imaging 
the animals from each group were sacrificed with CO2 inhalation and the colon tissue was 
dissected out longitudinally. Multiple longitudinal slices were taken for each imaging depth 
of the catheter and fixed in 10% formalin in order to correlate OCT findings with histology. 
3. Results 
3.1. Contrast agent binding study 
HT-29 and SW-480 colon cancer cell lines were used in our experiments to test contrast 
agent binding sensitivity and specificity. We have incubated over 20 slides for each type of 
cell line and carefully examined microparticle attachment to the cells. As a control we used 
blank (non-functionalized particles). Representative images showing the attachment of the 
MPs to the HT-29 cells and no attachment of the blank MPs are presented in Fig. 3. 
To determine binding efficiency and optimize incubation time we studied binding 
statistics for incubation times between 30 minutes and 3 hours. We took both bright field and 
fluorescence images and counted the fraction of the cells that were labeled with the contrast  
 
 
Fig. 3. Bright field and fluorescence images of HT-29 cells incubated with PCLMPs. A, A’ 
RGD-functionalized PCLMPs; B, B’ Blank PCLMPs. Magnification 20X. 
 
Fig. 4. Binding statistics and incubation time for the HT-29 and SW-480 cell lines 
RGD Functionalized MPs Blank MPs
A B A’ B’
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compared to the number of cells that were stained with functionalized MPs. A statistical 
analysis on over 20 slides (each cell type) showed that over 75% of the cells were labeled 
with MPs. The optimum incubation time was determined to be about 1.5 hrs (Fig. 4). These 
results demonstrate the successful functionalization of the MPs. More details about the 
testing of MPs on cell cultures and optimization approach for this contrast agent were 
presented elsewhere [22]. 
3.2. Ex vivo fluorescence-OCT imaging study 
The goal of this study was to preliminarily test the multimodal imaging approach, as well as 
the capability of OCT for differentiating between normal and abnormal colon tissue. At least 
two segments of the descending colon, about 10 mm in length, were analyzed from each 
animal. Besides the 785 nm fluorescence excitation and 1310 nm OCT imaging beams, an 
835 nm aiming beam was launched into the OCT channel of the imaging probe to make the 
OCT scan visible within the fluorescence image. An offset signal was generated for the OCT 
galvanometers to move the OCT scan to any region-of-interest (ROI) within the fluorescence 
image. The OCT images of each tissue specimen were finally correlated with histological 
findings by identifying India ink marks, which were placed during OCT imaging. 
The colon wall of the 6 BALB/c wild-type (control) mice and of 3 of the ApcMin mice, 
which did not show any sign of disease, was not notably stained with the contrast agent. 
However, consistent staining was observed in the remaining 12 ApcMin aged mice, with 
higher prevalence on the aged animals from the 2nd and 3rd group. The stained areas 
correlated very well with changes within colon wall morphology. Representative cases are 
presented in detail bellow. 
Normal colon:  A representative case of normal colon is shown in Fig. 5. The 
fluorescence image shows some fluorescence spots, indicating that a very small fraction of 
the MPs got attached to tissue. The OCT image shows the normal appearance of the mucosa 
(M), submucosa (SM), and muscularis propria (MP) layers. The SM layer was measured to 
be very thin in some specimens, and not always very well resolved by OCT. However, most 
of tissue boundaries remained clear and distinct at all depths within the colon. Due to the 
small fraction of the MPs attached to the normal colon, the OCT images did not show any 
area of increased scattering. 
 
Fig. 5. (A) Fluorescence image of the flattened colon showing very low attachment of the 
PCLMPs, as indicated by random bright spots. The vertical line indicates the position of the 
OCT scan, while the dashed line indicates the direction of this scan. (B) Cross-sectional OCT 
image showing the morphology of the colon layers; The OCT image displays the normal 
mucosa (M), the thin submucosal (SM) layer, and the muscularis propria (MP). The 
boundaries between these layers are well demarcated (see M/SM and SM/MP). (C) Colon 
histology within the ROI indicated in B. 
To further investigate if the same morphology is present on other areas of the tissue 
specimens, relatively dense raster scans (1024 x 256 pixels within a 2.5 mm x 1.75 mm area) 
were taken to better visualize morphologic details of the colon wall. Indeed, as shown in Fig. 
6, the two frames selected from Media 1 show the same morphology as it was observed in 
Fig. 5. Furthermore, similar morphology can be observed in all the frames from the raster 
scan. 
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Fig. 6. (Media 1). Fly-through video of both fluorescence and OCT measurements. (A) 
Fluorescence imaging showing the OCT raster scan, as indicated by the aiming beam. (B) 
Combined enface and cross-sectional OCT imaging. The en face view was taken at a depth 
indicated by the line from the cross-sectional image. The raw fluorescence video was acquired 
at 5 fps, while the raw OCT video was acquired at 20 fps. OCT scale bar = 250 μm. 
Very similar findings were observed in all 6 wild-type mice, as well as in 2 of the 8 
weeks old ApcMin mice and one 12 weeks old ApcMin mouse, which did not show any sign 
of adenomatous polyps. The absence of adenomatous polyps or carcinomas in ApcMin mice 
was noted by other investigators and explained by the fact that this animal model usually 
develops small intestine carcinomas, rather than colon adenomas or carcinomas [28]. 
Colon adenoma: The fluorescence images of the ApcMin mice that developed colonic 
adenomas showed substantially higher attachment of the MPs, especially in areas indicated 
by OCT as having changes in the morphology of the mucosal layer. These changes consisted 
of mucosal thickening over time (larger in older mice), or even growth of large polyps, and 
in some cases the disappearance of the mucosa/submucosa boundary. 
Figure 7 shows a representative case of a 12 weeks old ApcMin mouse, where the MPs 
attached preferentially (see red circled areas in (A)) in the two areas with increased thickness 
of the mucosal layer of the colon, as shown in the OCT image (B) and confirmed by 
histology (C). 
A raster scan over a larger area (~4 mm x 3mm) of the same tissue specimen shows 
indeed a good correlation between the brighter fluorescence areas and MP binding to tissue  
 
 
Fig. 7. (A) Fluorescence, (B) OCT, and (C) histology of adenoma (AD) in mouse upper colon. 
The adenoma almost triples the thickness of the mucosal layer in the inflamed area (mucosal 
thickening-MT). The adjacent normal mucosa (M), submucosa (SM), and muscularis propria 
(MP) are labeled. Accumulation of PCL microparticles (PCLMPs) in the adenoma area is 
visible in the OCT image and confirmed by histology. Individual PCLMPs are discernable in 
the magnified (x40) histology area. OCT scale bar: 250 μm; Histology magnification: 5x and 
40x, respectively 
 
Fig. 8. (A) Fluorescence image of a colon tissue specimen, (B) En face OCT image of the 
ROI indicated in A by a dotted rectangle. Cross-sectional images (B′ & B″) along the dotted 
lines from B show evident changes in the morphology of the mucosal layer, which are 
characteristic to adenomas. 
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MPs, while the cross-sectional images in areas indicated by the dotted lines show significant 
changes in the morphology of the mucosal layer (thickening of the mucosal layer, which is 
specific to adenomas). 
Besides mucosal thickening, adenomatous polyps, as large as 2 to 3 mm in diameter, 
were found in several mice with the age of 12 weeks or higher. These colonic polyps are 
overgrowths of the colonic mucosa that carry a small risk (< 1%) of becoming malignant. 
Such lesions are classified histologically as tubular adenomas, tubulovillous adenomas 
(villoglandular polyps), or villous adenomas. The likelihood of cancer in an adenomatous 
polyp at the time of discovery is related to size, histologic type, and degree of dysplasia. 
A representative case of an adenomatous polyp in a 12 weeks old ApcMin  mouse is 
shown in Fig. 9. The polyp invades the SM layer of the colon. The magnified histology 
image shows the disappearance of the lobular structure of the mucosal layer where the polyp 
is located. The presence of the MPs can be observed in both histology (darker spots) and 
OCT image (brighter spots on the top of the polyp), demonstrating the presence of the cancer 
receptors on these abnormal areas of the mouse colon. 
 
Fig. 9. OCT image and histopathology of adenomatous polyp. (A). OCT image of adenoma 
displays a markedly expanded mucosa (development of a large polyp) and not very  well 
defined tissue boundaries underlying the lesion. B.  Corresponding histopathology; B’. 
Magnified histology on the polyp area confirms the presence of adenoma. M- mucosa; SM-
submucosa; MP-muscularis  propria;  AD:  adenoma;  OCT  scale  bar:  500  μm;  Histology 
magnification: 5x and 20x, respectively. 
Colorectal adeno-carcinoma: The colorectal cancer, commonly known as bowel cancer, 
is a cancer caused by uncontrolled cell growth (neoplasia), in the colon, rectum, or 
vermiform appendix. Adenocarcinoma is a malignant epithelial tumor, originating from 
glandular epithelium of the colorectal mucosa. It invades the wall, infiltrating the MM, the 
SM[REMOVED HYPERLINK FIELD] and even the MP. Tumor cells describe irregular 
tubular structures, harboring pluristratification, multiple lumens, reduced stroma. Sometimes, 
tumor cells secrete mucus, which invades the interstitium producing large pools of 
mucus/colloid (optically “empty” spaces). 
Signs of colorectal adenocarcinoma were identified in only 2 ApcMin mice, 16 weeks 
old. The adenocarcinoma was invading and replacing all three layers of the rectum, as shown 
in Fig. 10. The OCT images showed the loss of tissue texture (absence of normal layers) and  
 
 
Fig. 10. Fluorescence (A), OCT image (B). and histopathology (C) of adenocarcinoma in 
mouse colorectal region. As observed, adenocarcinoma (ADC) was invading and replacing 
the all three layers: mucosa (M), Submicosa (SM) and muscularis propria (MP). OCT scale 
bar: 250 μm; Histology magnification: x10 and x40, respectively. 
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absorption in the necrotic tissue or by the presence of the pools of mucus. 
OCT raster scans (2.25 mm x 1.75 mm) were taken as well on the tissue specimens from 
the two ApcMin mice identified with colon adenocarcinoma. Very strong attachment of the 
MPs was observed in some areas, as shown in the two frames selected from Media 2 (see 
Fig. 11). The OCT images showed the loss of tissue texture (absence of normal layers). 
However, the presence of pockets of uneven echoic or dark areas was less prominent in this 
case, suggesting that cancer was not as advanced like it was observed in the previous case. 
 
Fig. 11. (Media 2). Fly-through video of both fluorescence and OCT measurements. (A) 
Fluorescence imaging showing the OCT raster scan, as indicated by the aiming beam. (B) 
Combined enface and cross-sectional OCT imaging. The en face view was taken at a depth 
indicated by the line from the cross-sectional image. The raw fluorescence video was acquired 
at 10 fps, while the raw OCT video was acquired at 20 fps. OCT scale bar: 250 μm. 
To further determine the correlation between tissue pathology and the integrated intensity 
of the fluorescence signal, a detailed analysis was performed on several tissue specimens that 
were assigned by a pathologist to one of the next classes: normal colon, adenomas, and 
adenocarcinomas. To account for the differences within specimen size, the contour of each of 
each tissue specimen was generated from the visible image and superimposed on the 
corresponding fluorescence image, as shown in Fig. 12. Then the background noise in each 
image was computed and extracted from the fluorescence signal. The integrated fluorescence 
signal was then calculated for each tissue specimen and normalized to specimen size. As 
observed, a clear difference has been obtained between the integrated fluorescence signals of 
the three pathologies. 
 
Fig. 12. (A, B, C) Representative fluorescence images for normal colon, colon adenoma, and 
colon adenocarcinoma. (A′, B′, C′) Processed images with removed background noise. (D) 
Integrated fluorescence signal for 11 specimens that were assigned to the three pathologies. 
These results suggest that enhanced contrast fluorescence imaging can be used to indicate 
cancer-suspect areas, while OCT imaging can be performed to further investigate these areas 
and detect alterations of the colon wall morphology. Quantitative OCT criteria can be 
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cancer. 
3.3 In-vivo OCT imaging study 
In vivo OCT imaging was performed in several mice, as discussed above. Two representative 
examples are presented below. 
I. Normal colon: The representative OCT-histology of the normal colon is shown in Fig. 
13. The OCT image shows the mucosa (M), submucosa (SM), muscularis propria (MP) 
layer, and the subserosa (SS)). The SS is a layer of tissue between the muscularis and serosa, 
which sometimes is admixed with some fat (F).Surprisingly, SS was not well differentiated 
in the animals investigated in the ex vivo OCT study. The SM was measured to be very thin 
in histology and not very well resolved in some of the OCT images. However, most of tissue 
boundaries remained clear and distinct at all depths, rotations, and time points. A highly 
scattering layer is observed on the top of the image; this is the OCT catheter protective 
Teflon tube. 
 
Fig. 13. OCT image (A) and histology (B) of normal colon. The OCT image displays the 
normal mucosa (M), the thin submucosal (SM) layer, the muscularis propria (MP), and the 
subserosa (SS) boundary with some underlying fat (F) or connective tissue layers. OCT scale 
bar: 250 μm; Histology magnification: 5x. 
II. Colon adenoma:  The OCT images of the ApcMin  mice that developed colonic 
adenomas showed substantial changes over the imaging time points. They consisted of 
mucosal thickening over time, or even growth of large polyps, and the disappearance of the 
mucosa/submucosa boundary. These changes in the mucosal-submucosal layers were more 
evident in the 12 weeks old ApcMin mice. All mice with the age of 12 weeks or higher have 
shown these changes. A representative example is shown in Fig. 14. 
 
Fig. 14. OCT (A) and histopathology (B) of adenoma in mouse upper colon. The adenoma 
almost triples the thickness of the mucosal layer in the inflamed area (mucosal thickening-
MT). The adjacent normal mucosa (M), submucosa (SM), and muscularis propria (MP) are 
labeled. OCT scale bar: 250 μm; Histology magnification: 5x and 20x, respectively. 
These examples demonstrate the suitability of OCT for in vivo  use to differentiate 
between various colon pathologies in small animals. However, OCT imaging through the 
instrument channel of a 2-3 mm endoscopic probe, suitable for small animal anatomy, will 
require further miniaturization of the fiber catheter. 
4. Discussion and Conclusions 
Among gastrointestinal (GI) cancers, colorectal cancer is the most prevalent one in the 
Western world, while gastric cancer is somewhat more prevalent in the Eastern world [29]. 
Prognosis is variable and depends almost entirely on the specific type of cancer. However, in 
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within the mucosa of the organ (stages I and II). Early stage cancer is usually curable with 
surgery [30]. If cancer is detected in later stages when it has already spread to regional lymph 
nodes (stage III), the cure rate degrades significantly [31]. Unfortunately, despite major 
advances in imaging, current endoscopic or radiologic imaging approaches may not detect 
these cancers in their early stage. 
Various radiologic and optical imaging approaches have been investigated previously to 
increase GI cancer diagnostic sensitivity and specificity. Among optical approaches, OCT 
has shown high promise in diagnosing GI cancers [17,18,32]. OCT imaging was also 
successfully combined with fluorescence spectroscopy, fluorescence molecular imaging, or 
fluorescence lifetime imaging to improve cancer detection sensitivity and specificity in the 
GI tract or in other organs [33–37]. However, considering the fact that OCT and either of 
these complementary optical modalities have a relatively small field of view (FOV),  it 
becomes impractical to use them for screening large organs without proper guidance. OCT 
use alone, or combined with any other small FOW optical spectroscopy or imaging method 
might become more appealing to the real clinical practice if a better guidance approach than 
current endoscopy becomes available. Therefore, the goal of this paper is to show that 
enhanced-contrast fluorescence imaging might be an appropriate tool for OCT guidance, and 
thus to limit its use to areas suspicious to adenoma or adenocarcinoma, as indicated by the 
fluorescence signal. Enhanced contrast fluorescence imaging might be possible by using a 
modified endoscope with and added fluorescence channel and either topical or i.v. 
administration of a cancer targeting agent loaded with a fluorophore. Previously, various 
contrast agents have been developed and tested in animal models to determine their 
suitability for GI cancer targeting [24,27,37]. Here we report on preliminary testing of a 
contrast agent based on micron-size MPs functionalized with an RGD peptide and loaded 
with a NIR dye, which has shown before promise in efficient targeting of various human 
cancer cell lines [22]. 
In this paper we summarize the results of an ex vivo fluorescence-guided OCT imaging 
study on BALB/c wild-type and ApcMin mice, where RGD functionalized PCLMPs were 
used as contrast agent to target activated colon cancer receptors. Although in vivo imaging 
would have been desirable, a combined fluorescence/OCT imaging probe suitable for small 
animal imaging was not available at the time this study took place. Such an endoscopic probe 
should have a maximum diameter of 3 mm and include an instrument channel for OCT 
imaging. OCT imaging was performed in both fluorescence-labeled and non-labeled areas of 
the colon and correlation with histological appearance of the colon wall was performed by a 
histopathologist blinded to OCT findings. Strong correlations between histology, 
fluorescently-labeled areas of the colon, and morphologic changes within the colon wall, as 
indicated by cross-sectional OCT imaging, were found. The OCT images of the 
fluorescently-labeled areas showed increased thickness of the mucosal layer of the colon, 
which is specific to adenomas, or uncontrolled cell growth (neoplasia), originating from 
glandular epithelium of the colorectal mucosa invading the submucosa or even muscularis 
propria, which is specific to adenocarcinoma. When quantifying the intensity of the 
fluorescence signal, a clear difference has been found between the three pathologies: weak 
background on the normal tissue, moderate signals from areas with adenomas, and strong 
signals from adenocarcinomas. 
In conclusion, a novel multimodal approach for diagnosis of early stage epithelial cancers 
has been investigated. It consisted of topical administration of RGD functionalized PCL 
microparticles and fluorescence-guided OCT imaging. Preliminary studies on cell lines and a 
mouse model of colon cancer showed that it is possible to selectively target cancer cells and 
highlight colon cancer locations in a fluorescence image. Although the contrast agent stains 
cancer very effectively, and thus biopsy can be performed under fluorescence guidance only, 
OCT imaging remains an essential tool in the diagnostic process because it supplements 
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provides the sub-cellular resolution needed to confirm or rule out cancer presence, but since 
it does not preserve well the morphology of the tissue, cancer depth spreading based on 
biopsy results is not accurate. Thus, the combination of OCT with biopsy can provide a more 
comprehensive set of data that will help clinicians to not only confirm cancer presence, but 
also determine its depth and lateral spreading. 
The proposed cancer screening approach needs to be further investigated in vivo in a 
larger pool of animals and in a larger diversity of tissue pathologies. Therefore, further in 
vivo testing of this approach is planned in an orthotopic mouse model of colon cancer. If 
successful, this screening approach could be translated to the clinical practice for improving 
the efficacy of current endoscopy procedures by better differentiation between normal and 
early stage cancerous lesions of the colon, especially in flat dysplasia. 
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